Medical Research Wiki

ALP / Cholesterol / Gut-Liver-Lipid Axis in UC

Properties1
tagsulcerative-colitis, ulcerative-proctitis, alp, alkaline-phosphatase, cholesterol, lipids, gut-liver-axis, bile-acids, psc, intestinal-alkaline-phosphatase

4 min read

ALP / Cholesterol / Gut-Liver-Lipid Axis in UC

Main digest: UC Causal Mechanism Digest 005 — ALP, Cholesterol, Gut-Liver-Lipid Axis

Working model

Paul’s ALP/cholesterol pattern should be treated as an objective biomarker branch of the central UC/proctitis theory.

UC/proctitis barrier failure + dysbiosis + inflammation
      ↓
gut-derived signals: LPS/endotoxin, cytokines, bile acid changes, permeability
      ↓
gut-liver axis / bile duct / lipid metabolism response
      ↓
possible changes in ALP, GGT, bilirubin, AST/ALT, albumin, lipids, ApoB/LDL markers

Key split: what kind of ALP?

Elevated serum ALP can come from multiple sources:

  • liver / bile ducts / cholestasis;
  • bone;
  • intestine;
  • mixed or transient sources.

For Paul, the most important next interpretive step is not “what does ALP mean?” but:

When ALP is high, is GGT also high? What are bilirubin, AST/ALT, ALP isoenzymes, bone markers, vitamin D/PTH, and calprotectin doing?

Why PSC is on the map

PSC matters because:

  • PSC is strongly associated with IBD/UC;
  • suspicion often involves cholestatic labs such as ALP/GGT/bilirubin;
  • MRCP/MRC is preferred diagnostic imaging when PSC is suspected;
  • small-duct PSC is a special case requiring clinician evaluation.

But PSC should be treated as a clinician-guided screening question, not an assumption. Most UC patients do not have PSC.

Why intestinal alkaline phosphatase matters

Intestinal alkaline phosphatase (IAP/IALP) is different from simply “serum ALP is high.” It is a gut brush-border enzyme involved in:

  • LPS detoxification;
  • tight-junction/barrier function;
  • microbiome regulation;
  • lipid absorption and luminal homeostasis.

This makes ALP biology conceptually relevant to UC barrier failure, even if Paul’s blood ALP source still needs fractionation.

IAP as a potential lever, not just a biomarker (2026-07-04)

Most of this page treats ALP as a readout. But IAP is also studied as a therapeutic target: because it detoxifies LPS and supports tight junctions, supplemental/oral IAP and IAP-preserving strategies have been explored to reduce endotoxin-driven inflammation and strengthen the barrier. This connects the ALP branch directly to the barrier branches Paul already prioritizes (mucus-phosphatidylcholine-barrier-uc, pathobiont-mucus-layer-ecology-uc) and to the sulfate-reducing-bacteria/IAP thread already logged as open question 16 in key-open-questions.

  • Framing shift: ask not only “what is my serum ALP telling me?” but “could distal barrier/LPS control be supported (diet, microbiome, or IAP-directed approaches) rather than only measured?”
  • Caveat: this is mechanistic/research-grade, evidence_level low/speculative for direct intervention; serum ALP is still not the same thing as intestinal IAP activity, and any intervention is a clinician conversation, not a self-directed one.

Cholesterol interpretation

Population-level IBD literature often reports lower total cholesterol, LDL, and HDL in IBD, especially active/severe disease.

Paul reports the opposite pattern: cholesterol spikes during flares and improves when symptoms are controlled.

That mismatch makes his pattern important but not yet explained. Candidate explanations to test:

  • family/genetic lipid risk;
  • diet shifts during flare/remission;
  • fasting status or weight changes;
  • sleep/stress/metabolic state;
  • thyroid/insulin resistance;
  • medication/supplement effects;
  • liver/bile acid metabolism;
  • inflammation-driven lipoprotein remodeling;
  • lab timing relative to flare onset/recovery.

Bile acid / microbiome axis

Bile acids connect liver, microbes, barrier function, immunity, and cholesterol metabolism.

In IBD, dysbiosis may reduce bile-acid-transforming bacteria, increasing primary/conjugated bile acids and reducing secondary bile acids. Bile-acid receptors such as FXR, TGR5, PXR, and VDR regulate immune and barrier pathways.

This is promising mechanistically, but not yet a direct treatment conclusion.

Tracking variables

For future Guava/manual tracking:

  • ALP with date and flare/remission status;
  • ALP isoenzymes / bone-specific ALP if available;
  • GGT;
  • bilirubin;
  • AST/ALT;
  • albumin;
  • CBC/platelets;
  • CRP/ESR;
  • fecal calprotectin;
  • total cholesterol, LDL-C, HDL-C, TG;
  • ApoB, LDL-P, Lp(a) if available;
  • fasting status and recent diet;
  • weight change;
  • sleep quality / CPAP metrics;
  • medication/supplement changes;
  • dairy/gluten exposure;
  • stool mucus/blood/constipation/rectal pain.

Clinician questions

  • Does Paul’s ALP pattern look hepatic/cholestatic, intestinal, bone, or mixed?
  • Should ALP isoenzymes/fractionated ALP be ordered?
  • Should GGT be paired with repeat ALP whenever ALP is high?
  • Is PSC screening or MRCP/MRC appropriate given UC context and ALP persistence?
  • Is small-duct PSC ever relevant if cholestatic labs persist but imaging is normal?
  • Could bone/vitamin D/PTH/thyroid explain ALP?
  • Are lipids truly rising with flares after controlling for fasting status, diet, weight, sleep, thyroid, and medications?

Graph View

Backlinks